Pharmaceuticals News and Research

RSS

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics Pharmaceuticals, Inc. today announced the completion of the treatment phase of a 1,034-patient, one-year, open-label, international, phase 3 safety study of methylnaltrexone bromide subcutaneous injection in chronic, non-malignant pain patients with opioid-induced constipation (OIC).

22 Sep 2010

Delphi Genetics licences StabyExpress technology for production of protein vaccines to GSK

Delphi Genetics SA has announced today the signature of a licensing agreement with GlaxoSmithKline for the use of the patented StabyExpress technology for the production of protein vaccines for human use.

22 Sep 2010

Researchers receive $634,000 grant to study environmental factors, MS progression

A $634,000 grant from the Department of Defense is allowing researchers at the University at Buffalo to investigate a trio of environmental factors and their influence on the progression of multiple sclerosis.

22 Sep 2010

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

22 Sep 2010

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

A potential immunotherapy, a new gene therapy, an enzyme inhibitor, and a compound originally isolated from a Chinese herb are among the latest approaches scientists are proposing to treat addiction.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).

22 Sep 2010

Merus partners with Innocoll to launch 3 advanced wound care products in Canada

Merus Labs International Inc. is pleased to announce that their wholly owned subsidiary, Merus Labs Inc. announces the execution of a definitive agreement with Innocoll Pharmaceuticals Limited to license in, on an exclusive basis, 3 advanced wound care products for the Canadian market. Furthermore, Innocoll agrees to grant to Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market.

22 Sep 2010

How Medicare changes are playing out for advocates and in the campaign season

News outlets track both concerns about how Medicare will fare as a result of the health law's changes and examine how other changes advanced by reform are being characterized during the election season.

22 Sep 2010

NPS Pharmaceuticals closes public offering of 7,912,000 common stock shares

NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.

22 Sep 2010

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.

22 Sep 2010

NIH awards UCSF $15.4 million to set up new National Center for Systems Biology

Cell biologists at UCSF have received $15.4 million from the National Institutes of Health to set up one of two new National Centers for Systems Biology, to study how cells respond to their environment - an emerging field of research that could revolutionize medicine by creating "smart cells" to deliver medications and other therapeutics more effectively.

22 Sep 2010

Sun Pharma completes acquisition of controlling stake in Taro

Sun Pharmaceutical Industries Ltd. today announced that it has completed the acquisition of a controlling stake in Taro Pharmaceutical Industries Ltd. pursuant to the Option Agreement entered into in 2007 with Taro's controlling shareholders led by Taro's Chairman, Dr. Barrie Levitt.

22 Sep 2010

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).

22 Sep 2010

HIV infection mystery revealed

In a new discovery, Melbourne researchers have found a mechanism by which the HIV virus can affect people. According to co-head of the Burnet Institute's Centre for Virology, Sharon Lewin, scientists have found out how HIV entered a group of cells in which the virus tends to persist in spite of antiviral treatment that reduces the virus to undetectable levels.

22 Sep 2010

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Sinobiopharma, Inc., a fully integrated and highly innovative specialty pharmaceutical company engaged in the research, development, manufacture, and marketing of biopharmaceutical products in China, announced financial results for the fiscal year ended May 31, 2010.

22 Sep 2010

Brown grants exclusive intellectual property license to Tivorsan Pharmaceuticals

Development of a potential treatment for the most common form of muscular dystrophy is moving into a new phase at Brown University. Brown has granted an exclusive license for the intellectual property to Tivorsan Pharmaceuticals, a startup firm that will strive to see it through human trials.

22 Sep 2010

Access enters $30M supply agreement for MuGard with RHEI

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.

21 Sep 2010

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Optimer Pharmaceuticals, Inc. today announced that it has submitted the first section of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI. Optimer anticipates completing the submission in the fourth quarter of 2010 and plans to request priority review, which, if granted, could lead to an FDA decision on the NDA in the second quarter of 2011.

21 Sep 2010

Pharmaceuticals News and Research

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Delphi Genetics licences StabyExpress technology for production of protein vaccines to GSK

Researchers receive $634,000 grant to study environmental factors, MS progression

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Merus partners with Innocoll to launch 3 advanced wound care products in Canada

How Medicare changes are playing out for advocates and in the campaign season

NPS Pharmaceuticals closes public offering of 7,912,000 common stock shares

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

NIH awards UCSF $15.4 million to set up new National Center for Systems Biology

Sun Pharma completes acquisition of controlling stake in Taro

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

HIV infection mystery revealed

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Brown grants exclusive intellectual property license to Tivorsan Pharmaceuticals

Access enters $30M supply agreement for MuGard with RHEI

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence